Informa
TIDES Asia: Oligonucleotide & Peptide Therapeutics
2026年2月24-26日
日本, 東京, Grand Nikko Tokyo Daiba

主要會議第3天

主要會議第3天
Concurrent Tracks
並行分會
7:45am - 8:10am25 分
Delivery Strategies and CMC Approaches
遞送策略和CMC方法
Registration and Coffee
報到與咖啡時光
    7:45am - 8:10am25 分
    Emerging Approaches for RNA
    RNA的新方法
    Registration and Coffee
    報到與咖啡時光
      8:10am - 8:15am5 分
      Delivery Strategies and CMC Approaches
      遞送策略和CMC方法
      Chairperson’s Remarks: Track 1
      主席致詞：分會1
        8:10am - 8:15am5 分
        Emerging Approaches for RNA
        RNA的新方法
        Chairman's Remarks: Track 2
        主席致詞：分會2
          8:15am - 8:45am30 分
          Delivery Strategies and CMC Approaches
          遞送策略和CMC方法
          Surface Avidity Optimization Drives Potent CAR-T Generation with Targeted LNPs
          優化表面親和性，透過靶向 LNP 推動有效的 CAR-T 生成
          • Hiroshi Yamada, PhD - Head of Drug Delivery Research and Development, Nitto Denko Corporation
          8:15am - 8:45am30 分
          Emerging Approaches for RNA
          RNA的新方法
          Low-cost Production of High-quality RNA Drug Substances
          低成本生產高品質RNA藥物原料
          • Adithya Nair - Research Associate, UK-SEA Vax Hub, The University of Sheffield
          8:45am - 9:15am30 分
          Delivery Strategies and CMC Approaches
          遞送策略和CMC方法
          FORCE Platform Enables TfR1-mediated Delivery of Therapeutics for Rare Neuromuscular Diseases
          FORCE平台實現了針對罕見神經肌肉疾病的TfR1介導的藥物遞送
          • Stefano Zanotti, PhD - VP, Head of Neuromuscular Research, Dyne Therapeutics
          8:45am - 9:15am30 分
          Emerging Approaches for RNA
          RNA的新方法
          CureVac's Tailored LNP Platforms for Prophylactic and Therapeutic mRNA Vaccine
          用於預防性和治療性 mRNA 疫苗的CureVac客製化 LNP 平台
          • Vusala Ibrahimova, Ph.D. - Research Scientist, CureVac SE
          9:15am - 9:45am30 分
          Delivery Strategies and CMC Approaches
          遞送策略和CMC方法
          An Overlapping Fragment Approach to Diastereomer Analysis: Sensitivity and Linearity
          用於非對映異構體分析的重疊和分級方法：靈敏度和線性
          • Matthew Quinn - Manager, Analytical Development, Global Nucleic Acid Therapies, Novo Nordisk
          9:15am - 9:45am30 分
          Emerging Approaches for RNA
          RNA的新方法
          Building a Clinically Ready mRNA Oncology Platform: Expression, Purity, Intradermal Delivery, and Translational Insights from a Government-Supported COVID Trial
          建構臨床就緒的mRNA腫瘤平台：政府資助的新冠病毒試驗上，純度、透皮給藥與轉化相關考察
          • Hirotsugu Tanaka, PhD - Chief Scientific Officer, Crafton Biotechnology
          9:45am - 10:15am30 分
          Delivery Strategies and CMC Approaches
          遞送策略和CMC方法
          Regulatory CMC Challenges and Strategies for Oligonucleotide and Peptide Programs under Accelerated Review
          迅速審查對象──寡核苷酸和胜肽計畫上的法規上CMC課題及策略
          • David Lin, PhD - President and Principal Consultant, TS Pharma Experts LLC
          9:45am - 10:15am30 分
          Emerging Approaches for RNA
          RNA的新方法
          Late Breaking Presentation
          最新簡報
            10:15am - 10:55am40 分
            Networking Refreshment Break with Poster and Exhibit Viewing
            社交茶歇 （包含參觀海報/展覽）
            Networking Refreshment Break with Poster and Exhibit Viewing
            社交茶歇 （包含參觀海報/展覽）
              10:20am - 10:35am15 分
              TIDES Talks in the Exhibit Hall
              展廳的TIDES演講
              Integrated LC/MS Strategies for Oligonucleotide Stability, Nitrosamine Risk Assessment
              用於評估寡核苷酸穩定性和亞硝胺風險的整合式液相層析-質譜聯用策略
              • Yusuke Jikumaru, PhD - Market Development Specialist, Agilent Technologies
              Concurrent Tracks
              並行分會
              10:55am - 11:00am5 分
              Oligonucleotide Track
              寡核苷酸分會
              Chairperson’s Remarks: Track 1
              主席致詞：分會1
                10:55am - 11:00am5 分
                Peptide Track
                胜肽分會
                Chairperson’s Remarks: Track 2
                主席致詞：分會2
                • El Djouhar Rekaï, PhD - Head of Peptide Process Development & Manufacturing, PolyPeptide Group
                11:00am - 11:30am30 分
                Oligonucleotide Track
                寡核苷酸分會
                Extending Oligonucleotide Delivery and Gene Knockdown to Specific Cell Types in Kidney
                擴展腎臟上特定細胞型的寡核苷酸遞送與基因敲低至腎臟中特定細胞類型
                • Alfica Sehgal, PhD - Chief Scientific Officer, Judo Bio
                11:00am - 11:30am30 分
                Peptide Track
                胜肽分會
                Enhancing GLP-1 Manufacturing: Addressing TFF Challenges
                提升GLP-1的生產：應對TFF挑戰
                • Martin Leuthold, PhD - Head of Filtration and Chromatography Consumables, Sartorius
                11:30am - 12:00pm30 分
                Oligonucleotide Track
                寡核苷酸分會
                Expanding RNA Editing Applications to Extrahepatic Cells and Tissue Types through AIMer Chemistry Design
                透過AIMer化學設計將RNA編輯應用拓展至肝外細胞和組織類型
                • Chikdu Shivalila, PhD - Senior Scientist, Biology, Wave Life Sciences
                11:30am - 12:00pm30 分
                Peptide Track
                胜肽分會
                PolyPeptide Key Technology Enablers to Speed Up IND and Early Clinical Trials
                加速IND和早期臨床試驗的PolyPeptide主要技術成功因素
                • Fabien Rousset, PhD - Global Director of Innovation, Polypeptide Group
                12:00pm - 12:30pm30 分
                Oligonucleotide Track
                寡核苷酸分會
                Harnessing VHH ‘Nanobody’ As a Delivery System to Cross the BBB
                利用VHH「奈米體」作為穿透BBB(血腦障壁)的傳遞系統
                • Paymaan Jafar-nejad, PhD - Executive Director, Neurology Research, Ionis Pharmaceuticals
                12:00pm - 12:30pm30 分
                Peptide Track
                胜肽分會
                Greener, Smarter Peptide Manufacturing: Advancing Sustainability and Quality
                更環保、更智慧的胜肽製造：提升永續性和品質
                • Anubrato Aich - Senior Project Manager, AmbioPharm
                12:30pm - 1:40pm70 分
                Oligonucleotide Track
                寡核苷酸分會
                Networking Luncheon with Poster and Exhibit Viewing
                交流午餐會 （包含參觀海報/展覽）
                  12:30pm - 1:40pm70 分
                  Peptide Track
                  胜肽分會
                  Networking Luncheon with Poster and Exhibit Viewing
                  交流午餐會 （包含參觀海報/展覽）
                    Concurrent Tracks
                    並行分會
                    1:40pm - 1:45pm5 分
                    Oligonucleotide Track
                    寡核苷酸分會
                    Chairperson's Remarks: Track 1
                    主席致詞：分會1
                      1:40pm - 1:45pm5 分
                      Peptide Track
                      胜肽分會
                      Chairperson’s Remarks: Track 2
                      主席致詞：分會2
                      • El Djouhar Rekaï, PhD - Head of Peptide Process Development & Manufacturing, PolyPeptide Group
                      1:45pm - 2:15pm30 分
                      Oligonucleotide Track
                      寡核苷酸分會
                      Precision-Engineered SNPD-siRNAs for Allele-Specific Silencing of Disease-Causing Mutations
                      用於致病突變的等位基因特異性沉默的精密工程 SNPD-siRNA
                      • Kumiko Ui-Tei, PhD - CTO, ANRis Therapeutics and Director/Professor NucleoTIDE & PepTIDE Drug Discovery Center, Institute of Science Tokyo
                      1:45pm - 2:15pm30 分
                      Peptide Track
                      胜肽分會
                      Driving Further Evolution in Peptide API Downstream Processing
                      推動胜肽 API 下游加工的進一步進化
                      • Yuta Hiroyama - Senior Scientist, Process Chemistry Group, R&D Department, PeptiStar
                      2:15pm - 2:45pm30 分
                      Oligonucleotide Track
                      寡核苷酸分會
                      Advancing RNA Therapeutics: Preclinical Translation of Antibody Oligonucleotide Conjugates (AOC)
                      RNA醫學的進步：AOC的臨床前翻譯
                      • Husam Younis, PhD - Senior Vice President, Development Science, Avidity Biosciences
                      2:15pm - 2:45pm30 分
                      Peptide Track
                      胜肽分會
                      Advancing Mid-sized Drug Discovery through Scalable Unnatural Amino Acid Technologies
                      透過可擴展的非天然胺基酸技術推進中型藥物研發
                      • Manabu Wadamoto, PhD - Chief Scientist, Chugai Pharmaceutical Co., Ltd.
                      2:45pm - 3:15pm30 分
                      Oligonucleotide Track
                      寡核苷酸分會
                      LC-HRMS Bioanalytical Strategies for Characterizing and Quantifying Antibody-Oligonucleotide Conjugate (AOC) Therapeutics
                      用於 AOC 藥物表徵和定量化的 LC-HRMS 生物分析策略
                      • Xin Zhang, PhD - Principal Scientist, Denali Therapeutics
                      2:45pm - 3:15pm30 分
                      Peptide Track
                      胜肽分會
                      A Bioproduction Platform to Generate Functionalized Disulfide-constrained Peptide Analogues
                      用於生成功能化二硫鍵約束肽類似物的生物生產平台
                      • Sunhee Hwang, PhD - Scientist 4, Genentech
                      3:15pm - 3:45pm30 分
                      Oligonucleotide Track
                      寡核苷酸分會
                      Networking Refreshment Break with Poster and Exhibit Viewing
                      社交茶歇 （包含參觀海報/展覽）
                        3:15pm - 3:45pm30 分
                        Peptide Track
                        胜肽分會
                        Networking Refreshment Break with Poster and Exhibit Viewing
                        社交茶歇 （包含參觀海報/展覽）
                          Concurrent Tracks
                          並行分會
                          3:45pm - 4:15pm30 分
                          Oligonucleotide Track
                          寡核苷酸分會
                          The Analytical Method Development Challenges of a Peptide PMO Conjugate, VP-001 for the Treatment of Retinitis Pigmentosa RP-11
                          開發用於治療色素性視網膜炎RP-11的VP-001（肽-PMO偶聯物）分析方法的課題
                          • Mark Anastasas - Group Lead Chemistry-QC, PYC Therapeutics
                          3:45pm - 4:15pm30 分
                          Peptide Track
                          胜肽分會
                          Antibody-inducing Peptide Using Universal Epitopes: Concept and Clinical Update
                          使用通用表位的抗體誘導肽：概念和臨床更新
                          • Hideki Tomioka, PhD - Director of the Board and CSO, FunPep Co., Ltd.
                          4:15pm - 4:45pm30 分
                          Oligonucleotide Track
                          寡核苷酸分會
                          Optimizing Oligo Protein Conjugates with Chemistry-Driven Solutions for Enhanced Properties and Scale-Up
                          透過化學驅動的解決方案優化寡核苷酸蛋白偶聯物，以提升性能並實現規模化生產
                          • Naresh Jain, PhD - CEO, NJ Bio
                          4:15pm - 4:45pm30 分
                          Peptide Track
                          胜肽分會
                          Late Breaking Presentation
                          最新簡報
                            4:45pm - 5:15pm30 分
                            Oligonucleotide Track
                            寡核苷酸分會
                            Precise Engineering and Structural Elucidation of Aptamer-Drug Conjugates (ApDC) for Implantable Triple-Negative Breast Cancer (TNBC) Therapy
                            闡明三陰性乳癌 （TNBC）植入治療上的ApDC精密工學與構造
                            • Jung Hwan Lee, PhD - CEO, Interoligo Corp.
                            4:45pm - 5:15pm30 分
                            Peptide Track
                            胜肽分會
                            Late Breaking Presentation
                            最新簡報
                              5:15pm - 5:20pm5 分
                              Oligonucleotide Track
                              寡核苷酸分會
                              Close of Conference
                              會議閉幕
                                5:15pm - 5:20pm5 分
                                Peptide Track
                                胜肽分會
                                Close of Conference
                                會議閉幕

                                  * 活動內容有可能不事先告知作更動及調整。

                                  主要會議第2天